Scisparc AAQS

Mitä Scisparc tekee? Scisparc Ltd., listed under the ticker SPRC with ISIN IL0010951403, is a biotechnology company headquartered in Tel Aviv-Yafo, Israel. The company operates in the healthcare sector and has a workforce of three employees. Scisparc Ltd. went public through an IPO on December 22, 2021. Its website is https://scisparc.com/. The company is engaged in the development of pharmaceutical products based on cannabinoid technologies, focusing on repurposing dronabinol for various medical conditions. Specific drug development programs include THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain treatment. Scisparc Ltd. is a clinical stage pharmaceutical company, indicating its focus on advancing drug candidates through clinical trials toward potential regulatory approval and commercialization. The company's activities are centered around leveraging cannabinoid-based approaches to address unmet medical needs in multiple therapeutic areas. Scisparc on yksi Eurpooliin suosituimmista yhtiöistä.